Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA2OWK)

• Drug Name: PMID18178086C15 Drug Info
• Synonyms: GTPL6993

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 73755255
  TTD Drug ID: DMA2OWK

Molecule-Related Drug Atlas

Drug(s) Targeting Lysophosphatidic acid receptor 2 (LPAR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LPA	DMI5XR1	Discovery agent	N.A.	Investigative	[2]
Ki16425	DMJTDK9	Discovery agent	N.A.	Investigative	[3]
2-oleoyl-LPA	DMN9OS1	Discovery agent	N.A.	Investigative	[4]
dodecyl-thiophosphate	DMAJVPI	Discovery agent	N.A.	Investigative	[5]
oleoyl-thiophosphate	DM1TAM9	Discovery agent	N.A.	Investigative	[5]
NAEPA	DM38XWZ	Discovery agent	N.A.	Investigative	[6]
BrP-LPA	DMPGEO1	Discovery agent	N.A.	Investigative	[7]
dodecylphosphate	DMPCLTW	Discovery agent	N.A.	Investigative	[8]
decyl dihydrogen phosphate	DMNKDT5	Discovery agent	N.A.	Investigative	[8]
GRI977143	DM3A0TE	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysophosphatidic acid receptor 2 (LPAR2)	TTB7Y8I	LPAR2_HUMAN	Antagonist	[1]

References

• [1] Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
• [2] Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3473-6.
• [3] Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
• [4] Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
• [5] Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
• [6] LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
• [7] Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
• [8] Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
• [9] Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73.